Clopidogrel plus proton pump inhibitor linked with increased risk for rehospitalization

May 2010
Hem/Onc Today;5/25/2010, Vol. 11 Issue 10, p8
The article discusses the study about the impact of taking clopidrogel combined with proton pump inhibitor on risk for rehospitalization following a myocardial infarction or stent placement by researchers from Irvine, California and Seattle.


Related Articles

  • Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. Douglas, Ian J.; Evans, Stephen J. W.; Hingorani, Aroon D.; Grosso, Anthony M.; Timmis, Adam; Hemingway, Harry; Smeeth, Liam // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/11/2012, Vol. 345 Issue 7869, p15 

    The article reports on research which was conducted to determine whether pharmacokinetic interaction between proton pump inhibitors and clopidogrel lead to harmful vascular events. A comparison between cohort and within person study designs was carried out as part of the research. The results...

  • The aspirin question.  // Consumer Reports on Health;Jun2013, Vol. 25 Issue 6, p6 

    The article reports on the prevalence of heart attacks and strokes among U.S. consumers and discusses the role that a low dose aspirin regimen can play in preventing heart attacks and strokes. A discussion of medical complications which can be associated with aspirin, and of aspirin alternatives...

  • PPIs and Clopidogrel: Do We Have to Worry? Kuritzky, Louis // OB/GYN Clinical Alert;Dec2009, Vol. 26 Issue 8, p23 

    The article reports on the pharmacological relation between proton pump inhibitor (PPI) and clopidogrel in the U.S. It mentions that the antiplatelet effect of clopidogrel depends on its conversion and activation through the 2C19 pathway of the P450 system where the blockade of this pathway...

  • ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use Abraham, Neena S; Hlatky, Mark A; Antman, Elliott M; Bhatt, Deepak L; Bjorkman, David J; Clark, Craig B; Furberg, Curt D; Johnson, David A; Kahi, Charles J; Laine, Loren; Mahaffey, Kenneth W; Quigley, Eamonn M; Scheiman, James; Sperling, Laurence S; Tomaselli, Gordon F // American Journal of Gastroenterology;Dec2010, Vol. 105 Issue 12, p2533 

    The article discusses the use of proton pump inhibitors (PPI) and thienopyridines as an alternative treatment for cardiovascular (CV) diseases. It says that clopidogrel is more effective than aspirin in reducing main CV events. It mentions the greater risk for gastrointestinal (GI) bleeding in...

  • Clinical: Journals Watch - Ligament damage and sunbeds. Croton, Lizzie // GP: General Practitioner;4/2/2010, p22 

    The article offers information on several studies conducted related to treatment of several health problems. It states that a study revealed the treatment of anterior cruciate injuries with the help of clopidogrel and proton pump inhibitors (PPI). It mentions the study that revealed the...

  • Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI. Granger, Christopher B. // Evidence Based Medicine;Oct2009, Vol. 14 Issue 5, p22 

    The article provides brief information on a study regarding the efficacy of concomitant use of proton pump inhibitor (PPI) with clopidogrel on patients who have history of myocardial infarction (MI). After a population-based, nested, and case-control study of 13,636 older patients in Ontario, it...

  • 2013 - Adding aspirin to clopidogrel worsened outcomes in PCI patients receiving oral anticoagulants. Brott, Brigitta C. // ACP Journal Club;6/18/2013, Vol. 158 Issue 12, p1 

    The article focuses on a medical research that examines the safety and efficacy of clopidogrel without aspirin in patients receiving oral anticoagulants and having percutaneous coronary intervention (PCI). It discusses the methodologies used in the study including randomized controlled trial. It...

  • Non-compliance and discontinuation increases the risk of cardiovascular events in patients receiving low-dose aspirin.  // Drugs & Therapy Perspectives;Nov2010, Vol. 26 Issue 11, p24 

    Low-dose aspirin is a highly effective therapy for the prevention of cardiovascular (CV) events in high-risk patients. However, poor compliance and discontinuation are common among patients receiving such therapy, which increases their risk of CV events.

  • Potential Interaction between Clopidogrel and Proton Pump Inhibitors. Howard, Patricia A.; Vacek, James L. // American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 6, p353 

    Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation. The antiplatelet action of clopidogrel is felt to be of critical importance for the reduction of abrupt thrombotic occlusion of stents, particularly with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics